In a filing, Mind Medicine Inc revealed its Chief Executive Officer Barrow Robert unloaded Company’s shares for reported $0.16 million on Mar 25 ’24. In the deal valued at $9.50 per share,16,519 shares were sold. As a result of this transaction, Barrow Robert now holds 580,202 shares worth roughly $5.35 million.
Then, Karlin Dan sold 6,578 shares, generating $62,491 in total proceeds. Upon selling the shares at $9.50, the Chief Medical Officer now owns 358,452 shares.
Before that, Barrow Robert sold 13,237 shares. Mind Medicine Inc shares valued at $48,050 were divested by the Chief Executive Officer at a price of $3.63 per share. As a result of the transaction, Barrow Robert now holds 596,721 shares, worth roughly $5.5 million.
Leerink Partners initiated its Mind Medicine Inc [MNMD] rating to an Outperform in a research note published on April 15, 2024; the price target was $20. A number of analysts have revised their coverage, including Canaccord Genuity’s analysts, who began to cover the stock in early December with a ‘”a Buy”‘ rating. RBC Capital Mkts started covering the stock on November 16, 2022. It rated MNMD as “an Outperform”.
Price Performance Review of MNMD
On Monday, Mind Medicine Inc [NASDAQ:MNMD] saw its stock fall -7.80% to $9.22. Over the last five days, the stock has gained 2.10%. Mind Medicine Inc shares have risen nearly 151.91% since the year began. Nevertheless, the stocks have risen 154.70% over the past one year. While a 52-week high of $12.22 was reached on 04/04/24, a 52-week low of $2.41 was recorded on 01/19/24. SMA at 50 days reached $8.93, while 200 days put it at $4.97. A total of 1.31 million shares were traded, compared to the trading of 0.65 million shares in the previous session.
Levels Of Support And Resistance For MNMD Stock
The 24-hour chart illustrates a support level at 8.86, which if violated will result in even more drops to 8.50. On the upside, there is a resistance level at 9.93. A further resistance level may holdings at 10.64. The Relative Strength Index (RSI) on the 14-day chart is 49.90, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.52, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 51.61%. Stochastics %K at 63.80% indicates the stock is a holding.
The most recent change occurred on August 26, 2022 when Oppenheimer began covering the stock and recommended ‘”an Outperform”‘ rating along with a $3.50 price target.
